Evidence map›Paper›PMID 32996774›Full record

ReviewAmerican journal of physiology. Lung cellular and molecular physiology2020

Vitamin D supplementation as a rational pharmacological approach in the COVID-19 pandemic.

León Ferder, Virna Margarita Martín Giménez, Felipe Inserra, Carlos Tajer, Laura Antonietti, Javier Mariani, Walter Manucha

Open access · hybridAbstract readReview
In one paragraph

Review in American journal of physiology. Lung cellular and molecular physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

León FerderMaimónides University, Buenos Aires, Argentina.
Virna Margarita Martín GiménezInstitute of Research in Chemical Sciences, School of Chemical and Technological Sciences, Cuyo Catholic University, San Juan, Argentina.
Felipe InserraMaimónides University, Buenos Aires, Argentina.
Carlos TajerDepartment of Cardiology, Hospital El Cruce Néstor C. Kirchner, Buenos Aires, Argentina.
Laura AntoniettiDepartment of Cardiology, Hospital El Cruce Néstor C. Kirchner, Buenos Aires, Argentina.
Javier MarianiDepartment of Cardiology, Hospital El Cruce Néstor C. Kirchner, Buenos Aires, Argentina.
Walter ManuchaPathology Department, Pharmacology Area, Medical Sciences College, National University of Cuyo, Mendoza, Argentina.ORCID 0000-0002-2279-7626
Hospital El Cruce · ARUniversidad Maimónides · ARConsejo Nacional de Investigaciones Científicas y Técnicas · ARUniversidad Católica de Cuyo · ARUniversidad Nacional Arturo Jauretche · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has reached most of the countries worldwide causing death, which often results from an inflammatory storm associated with severe acute respiratory syndrome (SARS). This has prompted researchers to seek specific novel and definitive treatments urgently. In this context, it is interesting to evaluate the preventive and therapeutic effects of existing pharmacological agents that could be useful. In this regard, vitamin D supplementation, particularly in individuals likely to be deficient, may be a promising option. Vitamin D is a hormone that modulates many of the same inflammatory and oxidative signaling pathways triggered during COVID-19. For example, vitamin D suppresses the actions of the renin-angiotensin system, which has a determining role in the pathophysiology of the inflammatory response related to COVID-19. This paper analyzes the evidence that vitamin D supplementation might be a valuable preventive/therapeutic measure in groups at risk for or infected with COVID-19. It also discusses how clinical studies could be best designed to evaluate the possible advantages of vitamin D supplementation for the benefit of public health during the pandemic.

Indexed as

Dietary SupplementsAnimalsCOVID-19HumansOxidative StressPandemicsRenin-Angiotensin SystemRespiratory Distress SyndromeSARS-CoV-2Vitamin DVitamin DCOVID-19inflammationoxidative stressrenin-angiotensin systemvitamin D

Identifiers

PMID32996774
PMCPMC7839598
OpenAlexW3091614907

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.